MiMedx to buy Sanara MedTech in cash-and-stock deal valued at USD 35 a share

• MIMEDX agreed to buy Sanara MedTech for USD 35 per share in cash and stock, valuing the deal at about USD 350 million.
• Consideration set at USD 33 in cash plus 0.4735 MIMEDX shares per Sanara share, based on a USD 4.22 reference price.
• MIMEDX expects to fund the cash portion with cash on hand, backed by a committed USD 300 million term loan from Hayfin.
• Deal aims to expand MIMEDX’s surgical footprint, nearly doubling surgical revenue; management targets 2027 revenue above USD 400 million.
• Run-rate cost synergies projected above USD 20 million; closing targeted by year-end, pending Sanara shareholder vote and regulatory clearances.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanara Medtech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607291601PRIMZONEFULLFEED9800423) on July 29, 2026, and is solely responsible for the information contained therein.